The phase III, double-blind KEYNOTE-826 trial of pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles plus platinum-based chemotherapy, with or without bevacizumab, showed ...

Advani shares his experience with cancer survivors and their fear of cancer recurrence and highlights an approach toward life that helps cope with the constant fear of recurrence, stress and anxiety.